GH Peptides for Body Recomposition: Hype vs Evidence

GH peptides raise growth hormone (GH) and insulin-like growth factor 1 (IGF-1), and the marketing leaps straight from there to dramatic muscle gain and fat loss. The evidence does not make that leap. Raising GH is real; meaningfully recomposing a healthy person's body with these compounds is mostly unproven, with tesamorelin's visceral-fat data being the one strong exception, and only in a specific population. None of them replace progressive resistance training and adequate protein, and most are not FDA-approved for recomposition, with several banned in sport.

What "body recomposition" actually means

Body recomposition, or recomp, means losing fat while holding or building muscle at the same time, so your body composition improves even if the scale barely moves. It is a real and worthwhile goal, and it is achievable with training and nutrition. The question this article tackles is narrower: do growth-hormone peptides meaningfully help, or is that a marketing story?

GH peptides do not supply growth hormone directly. They prompt your own pituitary to release more GH, which raises IGF-1, and GH and IGF-1 are genuinely involved in how the body builds muscle and handles fat. The marketing reasons backward from that biology: raise GH, therefore recomp the body. Biology is not destiny, though, and the size of any real-world effect is exactly what the evidence has to settle. For the deeper mechanism overview, see how growth-hormone peptides work.

The evidence, peptide by peptide

The honest picture varies a lot by compound, so it is worth going through them rather than treating "GH peptides" as one thing.

Tesamorelin has the strongest data, and it is the exception that proves the rule. In randomized controlled trials, it reduced visceral fat by roughly 15 to 18 percent versus placebo, but those trials were in adults with HIV-associated lipodystrophy, and tesamorelin is FDA-approved only for that condition. The result does not automatically transfer to healthy people seeking general fat loss. Our tesamorelin and visceral fat guide covers that nuance in full.

MK-677 (ibutamoren), an oral secretagogue rather than a peptide, has the most human data of the rest, and it is sobering. The best 12-month trial showed a small lean-mass gain of about 1.1 kg but no improvement in strength or function, plus some fat gain and worsened glucose control. That is the clearest evidence we have that raising GH and IGF-1 does not cleanly produce useful muscle. See the MK-677 guide for the full trial breakdown.

CJC-1295 and ipamorelin, especially as a stack, are the community favorites for recomp, and they have the least support. There are no published human combination trials, only mechanism plus anecdote. The case is entirely theoretical. We dig into that pairing in the CJC-1295 plus ipamorelin stack guide.

Sermorelin raises GH and IGF-1 in small studies but has no modern randomized-trial evidence for adult body-recomposition endpoints.

GH peptides by recomp claim versus evidence

Compound	Type	Claimed recomp benefit	Evidence strength	Approval status
Tesamorelin	GHRH analog	Visceral fat reduction	Strong, but only in HIV lipodystrophy	FDA-approved for that indication only
MK-677	Oral GH secretagogue	Muscle and lean mass	Lean-mass gain but no strength or function benefit	Not approved; WADA-banned
CJC-1295 + ipamorelin	GHRH + ghrelin secretagogue	Muscle gain, fat loss, recovery	Anecdotal; no human combination trials	Not approved; WADA-banned
Sermorelin	GHRH analog	Anti-aging, recomp	GH and IGF-1 rise; no recomp RCTs	Not currently approved; WADA-banned

This table compares claimed benefits and evidence, not doses. There is no validated recomposition dosing for any of these, and any figures online are conventions rather than recommendations.

Why "raises GH" does not equal "recomps you"

The gap between mechanism and outcome is the whole story here. GH and IGF-1 do influence muscle and fat, but a modest, pulsatile rise in your own GH from a secretagogue is a far cry from the supraphysiologic, continuous GH that recombinant human GH produces, and even that comes with serious downsides. The MK-677 trial is the cleanest illustration: a measurable lean-mass change with zero improvement in the things that actually matter, strength and function.

There is also a measurement trap. GH peptides can cause water retention and, in MK-677's case, appetite increase, so early scale or even lean-mass readings can overstate real, useful tissue change. This is exactly why fat-versus-muscle tracking beats bodyweight, the same lesson that applies to telling fat loss from muscle loss.

The placebo and novelty effects deserve a mention too, because they are strong with anything you inject on a schedule while also paying new attention to diet, training, and sleep. Someone who starts a GH-peptide protocol often tightens up everything else at the same time, eats more protein, lifts more consistently, sleeps more deliberately, and then credits the peptide for changes the fundamentals actually drove. Without a controlled comparison, it is genuinely hard to know what did what, which is part of why anecdote dominates this space and why honest measurement matters so much.

Another reason to be cautious is that GH and IGF-1 are not free levers you can pull without consequence. The same hormones that might, in theory, support muscle and fat metabolism also drive fluid retention, can raise blood glucose, and carry the theoretical concern of stimulating existing tumors. So even if a GH peptide produced a small recomposition benefit, that benefit has to be weighed against real risks, not treated as upside with no downside. A meaningful recomp tool would need to clear that bar, and the current evidence does not show that any of these do.

What actually drives recomposition

The unglamorous truth is that the proven recomposition levers are not peptides at all. Progressive resistance training supplies the signal that tells your body to keep and build muscle, and adequate protein supplies the raw material. Together they are the intervention with strong, replicated evidence across the literature. We cover the training half in resistance training to keep muscle.

GH peptides, at their honest best, are a small, unproven adjunct that might sit on top of those fundamentals under a clinician's direction. They are not a shortcut, and treating them as one usually means neglecting the things that actually work. For a realistic, peptide-specific take, see body recomposition with peptides, and for muscle-specific options, our best peptides for muscle ranking.

A useful gut check is to ask where the marginal effort should go. For almost everyone who has not yet nailed consistent resistance training, a protein intake in the range research associates with muscle preservation, and adequate sleep, the highest-return move is to build those habits, not to add a research chemical with thin evidence and real risk. The peptides are at best the last few percent of a strategy, and they are often promoted as the first move precisely because that framing sells better. Reversing that order is where most people go wrong.

It is also worth separating the "feel" of a protocol from its effect. GH-axis stimulation can produce noticeable short-term changes, a fuller, more pumped look from fluid shifts, or appetite and sleep changes, that feel like the compound is working. Those sensations are not the same as a durable change in your ratio of muscle to fat, and they can be actively misleading. The only way to know whether the underlying composition is moving is to measure it over time, which is the entire problem with judging recomp by mirror and scale.

Regulatory status and safety

No GH peptide is FDA-approved for body recomposition. Tesamorelin is approved only for HIV lipodystrophy; CJC-1295, ipamorelin, sermorelin, and MK-677 are not approved for any recomposition use, and most circulate as research chemicals with no quality oversight. Several, including CJC-1295, ipamorelin, tesamorelin, sermorelin, and MK-677, are on the WADA Prohibited List under category S2, banned at all times. If you are a tested athlete, the recomp question is moot.

On safety, GH-axis stimulation carries real class risks: fluid retention, carpal-tunnel-like numbness, elevated glucose and reduced insulin sensitivity, and the theoretical concern that raising IGF-1 could stimulate a pre-existing malignancy. Add the sourcing risks of gray-market products, variable purity and possible endotoxin contamination, and the case for clinician supervision is strong. The compounding landscape is shifting in 2026, so check FDA.gov for current status.

What to ask a provider

If you are exploring GH peptides for recomposition with a licensed clinician, useful questions include: Is there any human evidence this helps recomposition in someone like me? How would we separate real tissue change from water and appetite effects? How would we monitor IGF-1 and glucose? And have we maximized training and protein first? A provider experienced in hormonal or sports medicine is accountable for that decision in a way no article is.

The tracking angle

Recomposition is invisible on the scale, which is precisely the problem GH-peptide marketing exploits. Myo's fat-versus-muscle tracking, protein logging, and resistance-training log are exactly the data that reveal whether a provider-directed GH-peptide protocol is doing anything beyond placebo, water, and appetite. When your lean-mass trend, your protein intake, and your training sessions all sit in one place, "I think it is working" becomes a trendline you and your clinician can actually read.

That muscle-first lens is the whole point of Myo, the same approach it takes to GLP-1 muscle loss. The app tracks a protocol your provider has directed; it does not recommend, dose, or source anything.

References

• Published randomized controlled trials of tesamorelin in HIV-associated lipodystrophy reporting roughly 15 to 18 percent visceral fat reduction versus placebo.
• Nass R, et al. 12-month trial of oral MK-677 in older adults: lean-mass gain without strength or function improvement. Ann Intern Med (2008).
• US FDA. Pharmacy Compounding Advisory Committee status for CJC-1295, ipamorelin, and related peptides, 2024 to 2026. FDA.gov.
• World Anti-Doping Agency. 2026 Prohibited List, category S2 (GHRH analogs, GH secretagogues, and mimetics). wada-ama.org.